| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -4,997,735 | -4,348,373 | -3,948,165 | -7,508,117 |
| Stock based compensation | 444,525 | 283,205 | 182,188 | 681,843 |
| Amortization of intangibles | 25,000 | 25,000 | 25,000 | 50,000 |
| Realized and unrealized gain and accrued interest on investments | 110,527 | 77,044 | -2,185 | 140,996 |
| Increase (decrease) in accounts payable and accrued expenses | -200,904 | -258,491 | 1,427,052 | 156,567 |
| Decrease (increase) in prepaid expenses and other assets | 29,282 | 659,322 | -86,281 | -480,193 |
| Net cash used in operating activities | -4,868,923 | -5,035,025 | -2,225,459 | -6,280,510 |
| Purchase of investments | 980,685 | 12,264,069 | NaN | NaN |
| Proceeds from redemption of investments | 5,099,599 | 995,720 | 2,537,873 | 4,452,701 |
| Net cash provided by investing activities | 4,118,914 | -11,268,349 | 2,537,873 | 4,452,701 |
| Payment of amounts due to officers | 150,000 | 150,000 | 150,000 | 300,000 |
| Proceeds from sale of equity securities, net | NaN | 18,441,177 | 0 | 172,958 |
| Proceeds from exercise of warrants, net | 205,982 | NaN | NaN | NaN |
| Net cash provided by financing activities | 55,982 | 18,291,177 | -150,000 | -127,042 |
| Effect of foreign exchange rate on changes on cash | 454 | -613 | NaN | NaN |
| Net change in cash and cash equivalents | -693,573 | 1,987,190 | 162,414 | -1,954,851 |
| Cash and cash equivalents - beginning of period | 3,818,096 | 1,830,906 | 3,623,343 | NaN |
| Cash and cash equivalents - end of period | 3,124,523 | 3,818,096 | 1,830,906 | NaN |
Quoin Pharmaceuticals, Ltd. (QNRX)
Quoin Pharmaceuticals, Ltd. (QNRX)